- Cyclacel Pharmaceuticals (NASDAQ:CYCC) rises 5% premarket (on top of 10% in Monday's regular session) in what looks like a reaction to an initiation (Buy) at Janney Montgomery.
- Price target is $10.
- Bullish call is more than likely tied to the company's Phase 3 AML candidate sapacitabine.
Cyclacel Pharmaceuticals jumps on Janney initiation
Recommended For You
More Trending News
About CYCC Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
CYCC | - | - |
Cyclacel Pharmaceuticals, Inc. |